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Abstract
Recent clinical trials demonstrating the efficacy of poly(ADP-
ribose) polymerase (PARP) inhibitors for the treatment of BRCA1-
deficient breast cancer have provided support for the ‘synthetic
lethal’ concept of targeted cancer therapeutics. A new study
provides further preclinical validation of this concept by
demonstrating that BRCA1-deficient mouse mammary tumor cells
are selectively sensitive to an inhibitor of the polycomb gene EZH2.
The development of polycomb gene inhibitors may provide a novel
approach to selectively exploit the molecular alterations in BRCA1-
deficient breast tumors.
In the previous issue of Breast Cancer Research, Puppe and
colleagues [1] describe a novel approach to selectively target
BRCA1-deficient breast tumors. One of the most exciting
recent developments in clinical oncology has been the
demonstration of significant clinical efficacy of inhibitors of
poly(ADP-ribose) polymerase (PARP) in BRCA1-deficient
breast tumors [2]. The development of PARP inhibitors was
based on the concept of ‘synthetic lethality’, which posits that
a compound targeting a particular pathway may be selectively
‘lethal’ to cells harboring a mutation in a complementary
pathway. It was demonstrated, consistent with such a
concept, that cells lacking BRCA1 repair function were
1,000-fold more sensitive to PARP inhibition than cells with
intact DNA repair pathways [3,4]. Puppe and colleagues [1]
use a mouse model of BRCA1-deficient breast tumors to
identify  EZH2 as another ‘drugable’ synthetic lethal target.
They used expression profiling to identify EZH2 as a gene
that was significantly overexpressed in BRCA1-deficient
mouse mammary tumors as well as in breast tumors from
women with BRCA1 germline mutations. Importantly, cells
derived from BRCA1-deficient mouse mammary tumors were
20-fold more sensitive to the small-molecule EZH2 inhibitor
(DZNep) than were cells derived from mouse mammary
tumors with normal BRCA1 expression. The specificity of this
effect was demonstrated by similar ‘synthetic lethality’ of
BRCA1-deficient cells to EZH2 knockdown by a short
interfering RNA. Furthermore, this effect was reversed upon
restoration of BRCA1 expression.
EZH2 function
EZH2 is a subunit of the large ‘polycomb repressor complex
2’, which initiates gene silencing by trimethylating lysine 27 in
histone H3 (H3-K27 ME3). PRC1 complex genes, including
Bmi-1, are then recruited to these marked histone sites,
where they mediate repression of gene expression [5]. EZH2
has been reported to be expressed mainly in human basal
carcinomas, where this expression is associated with high
proliferation and poor patient outcome [6,7]. EZH2 has been
reported to regulate cell proliferation through interaction with
key growth-regulating pathways, including members of the
Rb family as well as Ink4A and Ink4B [5,8]. Although PRC2
and PRC1 polycomb genes function in a ‘linear fashion’ in
normal development, it has been suggested that their
overexpression may have different functional consequences
for breast tumorigenesis [9]. Nevertheless, both EZH2 and
Bmi-1 have been shown to play important roles in regulating
the self-renewal and differentiation of normal stem cells. This
occurs through modulation of stem cell self-renewal and
inhibition of genes promoting cellular differentiation [8].
BRCA1 and breast development
Recent studies have demonstrated that, in addition to its well-
known role in DNA repair, BRCA1 plays an important role in
breast development. Liu and colleagues [10] demonstrated
that BRCA1 regulates the differentiation of estrogen receptor
(ER)-negative breast stem cells into ER-positive luminal
progenitors. Recently, Lim and colleagues [11] reported that
breast tissue from BRCA1 mutation carriers contains
expanded luminal progenitor cells, suggesting a broader role
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for BRCA1 in the regulation of breast, stem, and progenitor
cells. Together, these studies suggest that the loss of
BRCA1 function may result in the expansion of the breast
stem and progenitor cell populations, providing targets for
further carcinogenic events. Although the exact relationship
between BRCA1 and EZH2 is not yet clear, Gonzalez and
colleagues [12] recently demonstrated that BRCA1 is
required for EZH2 to mediate proliferation in breast cancer
cell lines. Downregulation of EZH2 decreased the growth of
ER-negative breast cancer cells, an effect reversed by
BRCA1 knockdown.
Targeting of breast cancer ‘stem cells’
Recent studies have suggested that many tumors, including
those of the breast, may be initiated and maintained by a
cellular population that displays ‘stem cell’ properties. These
properties include self-renewal, which drives tumorigenesis,
and differentiation, which generates the non-self-renewing
population comprising the tumor bulk. Breast cancer stem
cells may mediate metastasis and contribute to treatment
resistance [13]. Although EZH2 and BRCA1 play a role in
the biology of normal stem cells, the role of these genes in
the regulation of breast cancer stem cells is not well defined.
It will be most interesting to determine whether EZH2 inhi-
bition is able to target ‘breast cancer stem cells’ in addition to
bulk cell populations in BRCA1-deficient tumors. The demon-
stration by Puppe and colleagues that DZNep reduced
tumorsphere formation, a property of stem cells, is consistent
with this possibility. However, the systemic toxicity of this
compound precluded its use in vivo, making an assessment
of its effect on ‘tumor initiating’ capacity difficult. An
additional important unanswered question is whether the
approach described by Puppe and colleagues will also show
utility in the therapy of sporadic basal breast tumors, many of
which have decreased BRCA1 activity as a result of gene
methylation [14]. EZH2 inhibition could potentially be
combined with PARP inhibition as a ‘double synthetic lethal’
strategy for the treatment of this category of breast tumors. In
any case, this study reinforces the feasibility of developing
‘synthetic lethal’ strategies aimed at selectively targeting
genetically altered cancer cell populations. Hopefully, these
strategies will result in the development of therapies that are
more effective and less toxic.
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